These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

901 related articles for article (PubMed ID: 12223530)

  • 21. Mediation of cell death by poly(ADP-ribose) polymerase-1.
    Koh DW; Dawson TM; Dawson VL
    Pharmacol Res; 2005 Jul; 52(1):5-14. PubMed ID: 15911329
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of Peroxynitrite-Induced Activation of Poly(ADP-Ribose) Polymerase (PARP) in Circulatory Shock and Related Pathological Conditions.
    Islam BU; Habib S; Ali SA; Moinuddin ; Ali A
    Cardiovasc Toxicol; 2017 Oct; 17(4):373-383. PubMed ID: 27990620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion.
    Szabó C; Dawson VL
    Trends Pharmacol Sci; 1998 Jul; 19(7):287-98. PubMed ID: 9703762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Poly (ADP-ribose) polymerase, nitric oxide and cell death.
    Pieper AA; Verma A; Zhang J; Snyder SH
    Trends Pharmacol Sci; 1999 Apr; 20(4):171-81. PubMed ID: 10322503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Caffeine metabolites are inhibitors of the nuclear enzyme poly(ADP-ribose)polymerase-1 at physiological concentrations.
    Geraets L; Moonen HJ; Wouters EF; Bast A; Hageman GJ
    Biochem Pharmacol; 2006 Sep; 72(7):902-10. PubMed ID: 16870158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation.
    Aguilar-Quesada R; Muñoz-Gámez JA; Martín-Oliva D; Peralta-Leal A; Quiles-Pérez R; Rodríguez-Vargas JM; Ruiz de Almodóvar M; Conde C; Ruiz-Extremera A; Oliver FJ
    Curr Med Chem; 2007; 14(11):1179-87. PubMed ID: 17504138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Poly (ADP-ribose) polymerase: An Overview of Mechanistic Approaches and Therapeutic Opportunities in the Management of Stroke.
    Tiwari P; Khan H; Singh TG; Grewal AK
    Neurochem Res; 2022 Jul; 47(7):1830-1852. PubMed ID: 35437712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
    Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of poly(ADP-ribose) polymerase-1 in CNS disease.
    Kauppinen TM; Swanson RA
    Neuroscience; 2007 Apr; 145(4):1267-72. PubMed ID: 17084037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention.
    Virág L; Szabó E; Gergely P; Szabó C
    Toxicol Lett; 2003 Apr; 140-141():113-24. PubMed ID: 12676457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Poly(ADP-ribosyl)ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions.
    Beneke S; Diefenbach J; Bürkle A
    Int J Cancer; 2004 Oct; 111(6):813-8. PubMed ID: 15300792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
    Iwashita A; Tojo N; Matsuura S; Yamazaki S; Kamijo K; Ishida J; Yamamoto H; Hattori K; Matsuoka N; Mutoh S
    J Pharmacol Exp Ther; 2004 Aug; 310(2):425-36. PubMed ID: 15075382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of nitrosative stress and poly(ADP-ribose) polymerase activation in myocardial reperfusion injury.
    Szabó G; Bährle S
    Curr Vasc Pharmacol; 2005 Jul; 3(3):215-20. PubMed ID: 16026318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy.
    Cepeda V; Fuertes MA; Castilla J; Alonso C; Quevedo C; Soto M; Pérez JM
    Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):39-53. PubMed ID: 18221025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel modulators of poly(ADP-ribose) polymerase.
    Szabo C; Pacher P; Swanson RA
    Trends Pharmacol Sci; 2006 Dec; 27(12):626-30. PubMed ID: 17055069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Neuronal death: potential role of the nuclear enzyme, poly (ADP-ribose) polymerase].
    Boulu RG; Mesenge C; Charriaut-Marlangue C; Verrecchia C; Plotkine M
    Bull Acad Natl Med; 2001; 185(3):555-63; discussion 564-5. PubMed ID: 11501263
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase.
    Endres M; Wang ZQ; Namura S; Waeber C; Moskowitz MA
    J Cereb Blood Flow Metab; 1997 Nov; 17(11):1143-51. PubMed ID: 9390645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological inhibition of poly(ADP-ribose) polymerase in cardiovascular disorders: future directions.
    Szabó C
    Curr Vasc Pharmacol; 2005 Jul; 3(3):301-3. PubMed ID: 16026326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Poly(ADP-ribose) polymerase inhibitors activate the p53 signaling pathway in neural stem/progenitor cells.
    Okuda A; Kurokawa S; Takehashi M; Maeda A; Fukuda K; Kubo Y; Nogusa H; Takatani-Nakase T; Okuda S; Ueda K; Tanaka S
    BMC Neurosci; 2017 Jan; 18(1):14. PubMed ID: 28095779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Minocycline protects cardiac myocytes against simulated ischemia–reperfusion injury by inhibiting poly(ADP-ribose) polymerase-1.
    Tao R; Kim SH; Honbo N; Karliner JS; Alano CC
    J Cardiovasc Pharmacol; 2010 Dec; 56(6):659-68. PubMed ID: 20881608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.